Subscribe To
MRUS / Strength Seen in Merus N.V. (MRUS): Can Its 37.5% Jump Turn into More Strength?
MRUS News
By Zacks Investment Research
October 17, 2023
Merus N.V. (MRUS) Soars 5.5%: Is Further Upside Left in the Stock?
Merus N.V. (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help t more_horizontal
By GlobeNewsWire
October 15, 2023
Merus Announces Business Update Conference Call
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinica more_horizontal
By Seeking Alpha
August 30, 2023
Merus: Petosemtamab And Zeno The Driving Forces Behind Investment Returns
Merus stock has cooled down after a strong rally, but long-term investors are sitting on a 47% gain since January. The company's pipeline includes pro more_horizontal
By Zacks Investment Research
August 7, 2023
Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to loss of $ more_horizontal
By Market Watch
June 29, 2023
Merus stock jumps 10% after FDA's action on cancer drug
Shares of Merus NV MRUS, +3.02% rallied as much as 10% in the extended session Thursday after the pharma company said the U.S. Food and Drug Administr more_horizontal
By Zacks Investment Research
May 11, 2023
Here's Why Merus N.V. (MRUS) is a Great Momentum Stock to Buy
Does Merus N.V. (MRUS) have what it takes to be a top stock pick for momentum investors? more_horizontal
By Zacks Investment Research
May 4, 2023
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $ more_horizontal
By Seeking Alpha
April 4, 2023
Merus: Dutch Drug Developer With An Interesting Platform
Merus N.V. develops bispecific and trispecific antibodies for cancer. They have deals with an array of big pharma. more_horizontal